These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20133495)

  • 41. Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.
    Hermann DJ; Krol TF; Dukes GE; Hussey EK; Danis M; Han YH; Powell JR; Hak LJ
    J Clin Pharmacol; 1992 Feb; 32(2):176-83. PubMed ID: 1613128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes.
    Brueckmann M; Bertsch T; Lang S; Sueselbeck T; Wolpert C; Kaden JJ; Jaramillo C; Huhle G; Borggrefe M; Haase KK
    Clin Chem Lab Med; 2004; 42(10):1132-9. PubMed ID: 15552272
    [TBL] [Abstract][Full Text] [Related]  

  • 43. β-Blocker treatment and prognosis in acute coronary syndrome associated with cocaine consumption: The RUTI-Cocaine Study.
    Cediel G; Carrillo X; García-García C; Rueda F; Oliveras T; Labata C; Serra J; Ferrer M; de Diego O; Bayés-Genís A
    Int J Cardiol; 2018 Jun; 260():7-10. PubMed ID: 29622456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intrapulmonary shunting during deliberate hypotension with nifedipine, diltiazem and labetalol in dogs.
    Casthely PA; Villanueva R; Rabinowitz L; Gandhi P; Litwak B; Fyman PN
    Can Anaesth Soc J; 1985 Mar; 32(2):119-23. PubMed ID: 3986650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beta-blockers for chest pain associated with recent cocaine use.
    Rangel C; Shu RG; Lazar LD; Vittinghoff E; Hsue PY; Marcus GM
    Arch Intern Med; 2010 May; 170(10):874-9. PubMed ID: 20498415
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative evaluation of the effects of labetalol, verapamil and diltiazem on antipyrine and indocyanine green clearances.
    Rocci ML; Vlasses PH; Lener ME; Fruncillo RA; Sirgo MA
    J Clin Pharmacol; 1989 Oct; 29(10):891-5. PubMed ID: 2592580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of labetalol treatment on the physiological and subjective response to smoked cocaine.
    Sofuoglu M; Brown S; Babb DA; Pentel PR; Hatsukami DK
    Pharmacol Biochem Behav; 2000 Feb; 65(2):255-9. PubMed ID: 10672977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Protective effect of labetalol on cardiovascular consequences of brain death in the swine].
    Mertes PM; el-Abbassi K; Siaghy EM; Delophont P; Michel C; Longrois-Undergureanu D; Carteaux JP; Villemot JP
    Ann Fr Anesth Reanim; 1997; 16(2):126-30. PubMed ID: 9686073
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Acute coronary syndrome and cocaine].
    Rodríguez-Esteban M; Mesa-Fumero J; Facenda-Lorenzo M; Dorta-Macías C; Ramos-López M; Soriano-Vela E
    Med Clin (Barc); 2009 Jun; 133(4):132-4. PubMed ID: 19371914
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative hemodynamic effects of urapidil and labetalol after electroconvulsive therapy.
    Blanch J; Martínez-Pallí G; Navinés R; Arcega JM; Imaz ML; Santos P; Faulí A; Bernardo M; Gomar C
    J ECT; 2001 Dec; 17(4):275-9. PubMed ID: 11731729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute Toxicity from Topical Cocaine for Epistaxis: Treatment with Labetalol.
    Richards JR; Laurin EG; Tabish N; Lange RA
    J Emerg Med; 2017 Mar; 52(3):311-313. PubMed ID: 27693072
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans.
    Boehrer JD; Moliterno DJ; Willard JE; Hillis LD; Lange RA
    Am J Med; 1993 Jun; 94(6):608-10. PubMed ID: 8506886
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Utility of cocaine drug screens to predict safe delivery of general anesthesia for elective surgical patients.
    Baxter JL; Alexandrov AW
    AANA J; 2012 Aug; 80(4 Suppl):S33-6. PubMed ID: 23248828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. β-Blockers, Cocaine, and the Unopposed α-Stimulation Phenomenon.
    Richards JR; Hollander JE; Ramoska EA; Fareed FN; Sand IC; Izquierdo Gómez MM; Lange RA
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):239-249. PubMed ID: 28399647
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of labetalol on cocaine pharmacokinetics in neonatal piglets.
    Scalzo FM; Primozic S; Burge LJ; Badger TM; Creer MH; Nehus C; Karba R
    Dev Pharmacol Ther; 1993; 20(1-2):54-63. PubMed ID: 7924765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Expert consensus document on Beta-adrenergic receptor blockers and cocaine use].
    Burillo-Putze G; Nogué-Xarau S; Suárez-Peláez J; Dueñas-Laita A
    Rev Esp Cardiol; 2007 Dec; 60(12):1334; author reply 1335. PubMed ID: 18082103
    [No Abstract]   [Full Text] [Related]  

  • 57. [Acute coronary syndrome and cocaine use: the tip of the iceberg].
    Burillo-Putze G; Miró O; Domínguez-Rodríguez A; Nogué Xarau S
    Med Clin (Barc); 2010 Oct; 135(11):527. PubMed ID: 19819482
    [No Abstract]   [Full Text] [Related]  

  • 58. [Acute coronary syndrome, a rare complication of human immunoglobulin therapy].
    Providência R; Fortuna J; Pereira AA; Mota P; Leitão-Marques AM
    Acta Reumatol Port; 2010; 35(1):90-4. PubMed ID: 20505634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic utility of the soluble CD40 ligand in acute coronary syndrome.
    Lindberg S
    Coron Artery Dis; 2014 Nov; 25(7):548-9. PubMed ID: 25248136
    [No Abstract]   [Full Text] [Related]  

  • 60. Phentolamine therapy for cocaine-association acute coronary syndrome (CAACS).
    Chan GM; Sharma R; Price D; Hoffman RS; Nelson LS
    J Med Toxicol; 2006 Sep; 2(3):108-11. PubMed ID: 18072128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.